CRISPR Therapeutics AG Net Profit Margin Growth & History (CRSP)
CRISPR Therapeutics AG's net profit margin was −16,569.77% for fiscal 2025.
View full CRISPR Therapeutics AG company overviewCRISPR Therapeutics AG annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −16,569.77% | −15588.23 pp |
| 2024 | 2024-12-31 | −981.54% | −940.16 pp |
| 2023 | 2023-12-31 | −41.38% | +54230.32 pp |
| 2022 | 2022-12-31 | −54,271.70% | −54312.98 pp |
| 2021 | 2021-12-31 | 41.28% | +48562.14 pp |
| 2020 | 2020-12-31 | −48,520.86% | −48543.95 pp |
| 2019 | 2019-12-31 | 23.09% | +5304.17 pp |
| 2018 | 2018-12-31 | −5,281.08% | −5114.35 pp |
| 2017 | 2017-12-31 | −166.74% | +282.08 pp |
| 2016 | 2016-12-31 | −448.82% | +9876.28 pp |
| 2015 | 2015-12-31 | −10,325.10% | — |
CRISPR Therapeutics AG quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −895.33% | +22484.60 pp |
| Q1 2026 | 2026-03-31 | −8,431.48% | +7290.60 pp |
| Q4 2025 | 2025-12-31 | −15,117.25% | −15012.71 pp |
| Q3 2025 | 2025-09-30 | −11,973.12% | +2302.96 pp |
| Q2 2025 | 2025-06-30 | −23,379.93% | +1070.36 pp |
| Q1 2025 | 2025-03-31 | −15,722.08% | +7411.05 pp |
| Q4 2024 | 2024-12-31 | −104.54% | −148.94 pp |
| Q3 2024 | 2024-09-30 | −14,276.08% | — |
| Q2 2024 | 2024-06-30 | −24,450.29% | −24339.23 pp |
| Q1 2024 | 2024-03-31 | −23,133.13% | −23080.07 pp |
| Q4 2023 | 2023-12-31 | 44.41% | +1842961.07 pp |
| Q2 2023 | 2023-06-30 | −111.06% | +117505.40 pp |
| Q1 2023 | 2023-03-31 | −53.07% | +19012.57 pp |
| Q4 2022 | 2022-12-31 | −1,842,916.67% | −1841821.64 pp |
| Q3 2022 | 2022-09-30 | −185,690.43% | −170259.24 pp |
| Q2 2022 | 2022-06-30 | −117,616.46% | −117700.75 pp |
| Q1 2022 | 2022-03-31 | −19,065.64% | +1929.35 pp |
| Q4 2021 | 2021-12-31 | −1,095.03% | +27834.43 pp |
| Q3 2021 | 2021-09-30 | −15,431.19% | +47027.59 pp |
| Q2 2021 | 2021-06-30 | 84.29% | +181120.66 pp |
| Q1 2021 | 2021-03-31 | −20,994.99% | +23419.66 pp |
| Q4 2020 | 2020-12-31 | −28,929.46% | −28969.12 pp |
| Q3 2020 | 2020-09-30 | −62,458.78% | −62524.10 pp |
| Q2 2020 | 2020-06-30 | −181,036.36% | −164149.89 pp |
| Q1 2020 | 2020-03-31 | −44,414.65% | −29656.11 pp |
| Q4 2019 | 2019-12-31 | 39.66% | +41422.27 pp |
| Q3 2019 | 2019-09-30 | 65.32% | +9072.60 pp |
| Q2 2019 | 2019-06-30 | −16,886.48% | −13358.90 pp |
| Q1 2019 | 2019-03-31 | −14,758.54% | −12674.59 pp |
| Q4 2018 | 2018-12-31 | −41,382.61% | −41383.04 pp |
| Q3 2018 | 2018-09-30 | −9,007.28% | −7972.22 pp |
| Q2 2018 | 2018-06-30 | −3,527.57% | −2904.60 pp |
| Q1 2018 | 2018-03-31 | −2,083.95% | −1289.46 pp |
| Q4 2017 | 2017-12-31 | 0.43% | −729.05 pp |
| Q3 2017 | 2017-09-30 | −1,035.06% | −87.36 pp |
| Q2 2017 | 2017-06-30 | −622.98% | +1535.14 pp |
| Q1 2017 | 2017-03-31 | −794.49% | +978.41 pp |
| Q4 2016 | 2016-12-31 | 729.48% | +5697.09 pp |
| Q3 2016 | 2016-09-30 | −947.71% | — |
| Q2 2016 | 2016-06-30 | −2,158.11% | — |
| Q1 2016 | 2016-03-31 | −1,772.90% | — |
| Q4 2015 | 2015-12-31 | −4,967.61% | — |
CRISPR Therapeutics AG net profit margin trends
Over the last five fiscal years, CRISPR Therapeutics AG's net profit margin increased from −48,520.86% to −16,569.77%, a change of +31951.09 percentage points. The latest reported quarter, Q2 2026, shows −895.33%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CRISPR Therapeutics AG source filings ↗